The Evidence for Disease Modification in Parkinson's Disease

REFERENCES

• Parkinson J. An essay on the shaking palsy. London: Sherwood, Neeley and Jones; 1817.
   Google Scholar
• Chrisp P, Mammen GJ, Sorkin EM. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991;1:228–48.
   PubMedGoogle Scholar
• Youdim MB, Bar AO, Yogev-Falach, Weinreb O, Maruyama W, Naoi M, Amit T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005;79:172–9.
   PubMedGoogle Scholar
• Zou L, Jankovic J, Rowe DB, Xie W, Appel S, Le W. Neuroprotection of pramipexole against dopamine and levodopa-induced cytotoxicity. Life Sci. 1999;64:1275–85.
   PubMedGoogle Scholar
• Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl- 1,2,3,6 tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic neurons in aged mice. Brain Res. 1998;783:109–14.
   PubMedGoogle Scholar
• The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989 Nov 16;321(20):1364–71.
   PubMedGoogle Scholar
• The Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993:328;176–83.
   Google Scholar
• The Parkinson's Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol. 1996;39:29–36.
   PubMedGoogle Scholar
• The Parkinson's Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa. Ann Neurol. 1996:39:37–45.
   Google Scholar
• Palhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R; Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms Parkinson's disease. Neurology. 2006;66:1200–06.
   Google Scholar
• Leber P. Slowing the progression of Alzheimer's disease: methodological issues. Alzheimer Dis Assoc Dis. 1997;11 Suppl 5:S10–21.
   Google Scholar
• Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989;245:519–22.
   PubMedGoogle Scholar
• Rascol O. “Disease modification” trials in Parkinson's disease: target populations, endpoints and study design. Neurology. 2009:72:S51–8.
   Google Scholar
• The Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO study. Arch Neurol. 2002;59:1937–43.
   PubMedGoogle Scholar
• The Parkinson Study Group. A controlled, randomized, delayed start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561–6.
   PubMedGoogle Scholar
• Hauser RA, Lew MF, Hurtig HI, Ondo W, Wojcieszek J, Fitzer-Attas CJ, on behalf of the TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009;24:564–73.
   PubMedGoogle Scholar
• Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, for the ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268–78.
   PubMedGoogle Scholar
• Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord. 2010 Aug 15;25(11):1627–32.
   PubMedGoogle Scholar
• Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K, on behalf of the PROUD Study Group. Immediate vs. delayed start pramipexole in early Parkinson's disease: the PROUD Study (poster 1.278). Poster session presented at: WFN XVIII World Congress on Parkinson's Disease and Related Disorders; 2009 Dec 13–16; Miami, FL.
   Google Scholar
• The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498–508.
   PubMedGoogle Scholar
• Fahn S; The Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol. 2005;252 Suppl 4: IV/37-42.
   PubMedGoogle Scholar
• Parker WJ Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26:719–23.
   PubMedGoogle Scholar
• Kridge D, Carroll MT, Cooper JM, Marsden CD, Schapira AHV. Platelet mitochondrial function in Parkinson's disease. Ann Neurol. 1992;32:782–8.
   PubMedGoogle Scholar
• Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with activities of complexes I and II/III in mitochondria from parkinsonian and non-parkinsonian subjects. Ann Neurol. 1997;42:261–4.
   PubMedGoogle Scholar
• Schults C, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; The Parkinson Study Group. Effects of Coenzyme Q10 in early Parkinson's disease: evidence of slowing the functional decline. Arch Neurol. 2002;59:1541–50.
   PubMedGoogle Scholar
• Beale C, Shoulson I, Oakes D; NINDS. Effects of Coenzyme Q10 in Parkinson disease [Internet]. Bethesda (MD): National Institutes of Health (NIH). 2008 - [2011 Sept 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT00740714.
   Google Scholar
• Beale C, Shoulson I, Oakes D; NINDS. Effects of Coenzyme Q10 in Parkinson disease. Statement on the termination of the QE3 Study [Internet]. Bethesda (MD): National Institutes of Health (NIH) Neurological Institute. 2011 May 27 [updated 2011 Jun 2; 2011 Sept 22]. Available from: http://www.ninds.nih.gov/disorders/clinical_trials/CoQ10-Trial-Update.htm.
   Google Scholar
• NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006 Mar 14;66(5):664–71.
   PubMedGoogle Scholar
• NINDS NET-PD Investigators. A randomized clinical trial of Coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007 Jan 2;68(1):20–28.
   Google Scholar
• NINDS NET-PD Investigators. NET-PD LS-1 creatine in Parkinson's disease [Internet]. Bethesda (MD): National Institutes of Health (NIH) Neurological Institute. [2011 Sept 22]. Available from: http://www.ninds.nih.gov/disorders/ clinical_trials/NCT00449865.htm.
   Google Scholar
• Fisher BE, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul C, Jakowec MW. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res. 2004;77:378–90.
   PubMedGoogle Scholar
• Fisher BE, Wu AD, Salem GJ, Song J, Lin J, Yip J, Cen S, Gordon J, Jakowec M, Petzinger G. The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson's disease. Arch Phys Med Rehabil. 2008 Jul;89(7):1221–29.
   Google Scholar
• Petzinger GM, Fisher BE, Van Leeuwen JE, Vukovic M, Akopian G, Meshul CK, Holschneider DP, Nacca A, Walsh J, Jakowec MJ. Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson's disease. Mov Disord. 2010;25 Suppl 1:S141–5.
   PubMedGoogle Scholar
• Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ. “Rejuvenation” protects neurons in mouse models of Parkinson's disease. Nature. 2007;447:1081–6.
   PubMedGoogle Scholar
• Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov Disord. 2010;25 Suppl 1:S63–70.
   PubMedGoogle Scholar
• The Parkinson Study Group; Michael J; Fox Foundation for Parkinson's Research and Northwestern University; Simuni T. Safety, tolerability and efficacy assessment of Dynacirc CR in Parkinson's disease (STEADY-PD) [Internet]. Bethesda (MD): National Institutes of Health (NIH).2009-[2011 Sept 22]. Available from: http://clinicaltrials.gov/ct2/show?term=isradipine&rank=2.
   Google Scholar
• Schwarzschild M, Michael J; Fox Foundation for Parkinson's Research. Safety of urate elevation in Parkinson's disease (SURE-PD) [Internet]. Bethesda (MD): National Institutes of Health (NIH).2009 - [2011 Sept 22]. Available from: http://www.pdtrials.org/en/browse/all/view/259.
   Google Scholar
• Yeum KJ, Russell RM, Krinsky NI, Aldini G. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys. 2004;430:97–103.
   PubMedGoogle Scholar
• Luo W, Schwarzschild MA, Xu K. Urate attenuates MPTP-induced dopaminergic neurotoxicity in mice [abstract no. 797.8]. Paper presented at: Annual Meeting of the Society for Neuroscience; 2007 Nov 3-7; San Diego, CA.
   Google Scholar
• Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166:561–7.
   PubMedGoogle Scholar